



Review Article

Harnessing the Therapeutic Potential of Plant-Derived Natural Products in Neurological Disorders

Sandeep Prakash¹, Soumya Verma^{2*}

¹DKRR Pharmacy Shikshan Sansthan, Sitapur, Uttar Pradesh, India

²Era College of Pharmacy, Era University Lucknow, Uttar Pradesh, India

ARTICLE INFO

Article history:

Received: 09 February, 2024

Revised: 07 March, 2024

Accepted: 27 March, 2024

Published: 20 June, 2024

Keywords:

Natural Products, Neurological Disorders, Neuroprotection, Phytochemicals, Neuropharmacology.

ABSTRACT

Neurological disorders represent a significant healthcare burden globally, necessitating the exploration of novel therapeutic approaches. Plant-derived natural products have garnered increasing attention for their potential in managing neurological disorders due to their diverse chemical structures and pharmacological activities. This review provides a comprehensive overview of the therapeutic potential of plant-derived natural products in neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression. It discusses the bioactive compounds isolated from various plant sources, such as flavonoids, alkaloids, terpenoids, and polyphenols, elucidating their mechanisms of action and neuroprotective effects. Furthermore, the review highlights the preclinical and clinical evidence supporting the efficacy of plant-derived natural products in mitigating neuroinflammation, oxidative stress, excitotoxicity, and neurodegeneration. Additionally, it explores the synergistic interactions between natural products and conventional neuropharmacological agents, offering insights into combination therapies for enhanced therapeutic outcomes. Challenges associated with the standardization, formulation, and bioavailability of plant-derived natural products are also addressed, along with future perspectives on their development as potential neurotherapeutics. Overall, this review underscores the promise of plant-derived natural products as valuable sources of novel drug candidates for the management of neurological disorders, providing a roadmap for future research and clinical translation.

INTRODUCTION

Neurological disorders impose a substantial burden on global public health, affecting millions of individuals worldwide and posing significant challenges to healthcare systems (WHO, 2020). Despite advancements in medical research and therapeutic interventions, the management of conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression remains a formidable task, necessitating the exploration of innovative treatment strategies (Kalia and Lang, 2015). In recent years, there has been growing interest in the therapeutic potential of plant-derived natural products as promising candidates for the management of neurological disorders (Howes and Houghton, 2003).

Plants have long been recognized as valuable sources of bioactive compounds with diverse chemical structures and pharmacological activities (Newman and Cragg, 2016). These natural products exhibit a wide range of neuroprotective effects, including antioxidant, anti-inflammatory, anti-apoptotic, and neurotrophic properties, making them attractive targets for drug discovery and development (Sarris *et al.*, 2013). This comprehensive review aims to provide an in-depth exploration of the therapeutic potential of plant-derived natural products in neurological disorders, with a focus on Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression. By examining the bioactive compounds isolated from various plant sources

*Corresponding Author: Soumya Verma

Address: Era College of Pharmacy, Era University Lucknow, Uttar Pradesh, India

Email ✉: soumya.verma18@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2024 Sandeep Prakash *et al.* This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

and elucidating their mechanisms of action, this review seeks to shed light on the underlying pharmacological basis of their neuroprotective effects (Naoi and Maruyama, 2009). Furthermore, the review will discuss the preclinical and clinical evidence supporting the efficacy of these natural products in mitigating key pathogenic mechanisms associated with neurological disorders, including neuroinflammation, oxidative stress, excitotoxicity, and neurodegeneration (Wang *et al.*, 2014).

Through a critical analysis of the existing literature, this review will also address the challenges and limitations associated with the development of plant-derived natural products as neurotherapeutics, including issues related to standardization, formulation, and bioavailability (Butterweck and Nahrstedt, 2010). By providing insights into the potential synergistic interactions between natural products and conventional neuropharmacological agents, as well as highlighting future research directions and clinical translation, this review aims to contribute to the advancement of novel therapeutic strategies for neurological disorders (Raskin *et al.*, 2002).

Neurological disorders encompass a broad spectrum of conditions characterized by dysfunction in the nervous system, affecting cognition, motor function, behavior, and overall quality of life (WHO, 2020). Despite extensive research efforts and therapeutic advancements, the management of neurological disorders remains a significant challenge, necessitating the exploration of alternative treatment strategies (Kalia and Lang, 2015). In recent years, there has been growing interest in the therapeutic potential of plant-derived natural products in addressing neurological disorders, owing to their diverse chemical composition and pharmacological activities (Howes and Houghton, 2003).

Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive cognitive decline and neurodegeneration. Plant-derived natural products, such as flavonoids and polyphenols, have attracted attention for their neuroprotective effects in AD models. For instance, flavonoids, abundant in fruits and vegetables, exhibit antioxidant and anti-inflammatory properties, potentially mitigating neuroinflammation and oxidative stress, key contributors to AD pathogenesis (Butterweck and Nahrstedt, 2010). Polyphenols, found in tea, berries, and nuts, have demonstrated neuroprotective effects (Figure 1) through modulation of amyloid-beta aggregation and tau phosphorylation, hallmark pathological features of AD (Newman and Cragg, 2016).

Parkinson's disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuron loss and motor dysfunction. Several plant-derived compounds, including alkaloids and terpenoids, have shown promise in PD models. Alkaloids, such as caffeine and nicotine, exert neuroprotective effects through adenosine and nicotinic acetylcholine receptor modulation, respectively, offering

potential therapeutic avenues for PD management (Sarris *et al.*, 2013). Terpenoids, present in herbs and spices, possess antioxidant and anti-inflammatory properties, attenuating neuroinflammation and oxidative stress associated with PD pathogenesis (Naoi and Maruyama, 2009).

Epilepsy is a chronic neurological disorder characterized by recurrent seizures, resulting from abnormal neuronal excitability. Plant-derived natural products, such as cannabinoids and alkaloids, have emerged as potential antiepileptic agents. Cannabinoids, derived from *Cannabis sativa*, exert anticonvulsant effects through modulation of endocannabinoid signaling pathways, offering novel therapeutic approaches for epilepsy treatment (Wang *et al.*, 2014). Alkaloids, including berberine and vincristine, exhibit antiepileptic properties via inhibition of voltage-gated sodium channels and enhancement of gamma-aminobutyric acid (GABA)ergic transmission, respectively (Raskin *et al.*, 2002).

Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disorder characterized by inflammation and neurodegeneration in the central nervous system. Plant-derived compounds, such as polyphenols and cannabinoids, have demonstrated neuroprotective effects in MS models. Polyphenols, abundant in fruits and vegetables, exhibit anti-inflammatory and immunomodulatory properties, potentially attenuating neuroinflammation and autoimmune responses implicated in MS pathogenesis (Russo, 2008). Cannabinoids, through modulation of cannabinoid receptors and immune cell function, offer potential therapeutic benefits in MS management (Russo, 2011).

Depression is a prevalent mood disorder characterized by persistent feelings of sadness, hopelessness, and impaired functioning. Plant-derived natural products, including flavonoids and terpenoids, have garnered interest for their antidepressant effects. Flavonoids, present in fruits, vegetables, and herbs, exhibit antidepressant-like effects through modulation of neurotransmitter levels and neuroplasticity mechanisms (Sarris *et al.*, 2012). Terpenoids, such as ginsenosides and curcuminoids, possess antidepressant properties via regulation of monoamine neurotransmitters and neurotrophic factors, offering potential adjunctive therapies for depression (Gertsch, 2008).

Overall, the burgeoning research on plant-derived natural products underscores their therapeutic potential in neurological disorders, providing a rich source of novel drug candidates for future drug development and clinical translation (Table 1).


Applications

Alzheimer's Disease

Plant-derived compounds like curcumin from turmeric have shown promise in inhibiting the formation of beta-amyloid plaques, a hallmark of AD pathology (Lim *et al.*, 2001).

Table 1: Therapeutic potentials of plant-derived natural products in neurological disorders

Neurological disorder	Plant-derived natural product	Mechanism of action
Alzheimer's disease	Curcumin (from turmeric)	Anti-inflammatory, antioxidant, inhibition of beta-amyloid aggregation
	Ginkgo biloba extract	Vasoregulatory effects, antioxidant, improvement of cerebral blood flow
Parkinson's disease	L-dopa (from <i>Mucuna pruriens</i>)	Precursor to dopamine synthesis, alleviation of motor symptoms
	Resveratrol (from grapes)	Antioxidant, anti-inflammatory, modulation of neurotrophic factors
Epilepsy	Cannabidiol (from cannabis)	Modulation of neurotransmitter release, inhibition of seizure activity
	Quercetin (from fruits)	Antioxidant, inhibition of neuroinflammation, regulation of ion channels
Multiple sclerosis	Fingolimod (from fungus)	Immunosuppressive effects, modulation of sphingosine-1-phosphate receptors
	Epigallocatechin gallate (from green tea)	Anti-inflammatory, antioxidant, neuroprotective effects
Depression	St. John's wort extract	Inhibition of serotonin reuptake, modulation of neurotransmitter levels
	Saffron extract	Serotonergic and noradrenergic modulation, antioxidant properties

**Figure 1:** Various Pathological processes Modulated by Plant-derived natural products

Ginkgo biloba extract has been studied for its potential to improve memory and cognitive function in AD patients (Birks & Grimley Evans, 2009).

Parkinson's Disease

Compounds such as L-DOPA from *Mucuna pruriens* are used as dopaminergic agents to alleviate motor symptoms in PD (Katzenschlager *et al.*, 2004).

Resveratrol, found in grapes, exhibits neuroprotective effects and may help mitigate oxidative stress in PD (Blanchet *et al.*, 2008).

Epilepsy

Cannabidiol (CBD) from cannabis has shown anticonvulsant properties and is being investigated as a potential treatment for drug-resistant epilepsy (Devinsky *et al.*, 2017).

Flavonoids like quercetin, found in fruits and vegetables, have demonstrated anti-seizure effects through modulation of ion channels (Gupta *et al.*, 2002).

Multiple Sclerosis

Fingolimod, derived from a fungus, is an immunomodulatory

agent approved for the treatment of relapsing forms of MS (Cohen *et al.*, 2010).

Epigallocatechin gallate (EGCG) from green tea exhibits anti-inflammatory properties and may help protect against neurodegeneration in MS (Aktas *et al.*, 2004).

Depression

St. John's Wort extract has been used traditionally to alleviate symptoms of depression, possibly by inhibiting serotonin reuptake (Butterweck *et al.*, 2003).

Saffron extract has shown antidepressant effects through modulation of neurotransmitter levels (Hausenblas *et al.*, 2013).

Advantages

Natural Source

Plant-derived natural products are often perceived as safer alternatives to synthetic drugs due to their natural origin (Fabricant and Farnsworth, 2001).

Diverse Pharmacological Activities

Natural products possess a wide range of pharmacological activities, including antioxidant, anti-inflammatory, and neuroprotective effects, making them versatile candidates for neurological disorders (Newman & Cragg, 2016).

Potential Synergistic Effects

Many natural products contain multiple bioactive compounds that may exert synergistic effects, enhancing therapeutic efficacy (Wagner & Ulrich-Merzenich, 2009).

Cultural and Traditional Use

Some plant-derived remedies have been used in traditional medicine for centuries, providing a rich source of empirical knowledge for drug discovery (Farnsworth *et al.*, 1985).

Relatively Low Cost

Compared to synthetic drugs, the production of plant-derived natural products may involve lower costs, potentially increasing accessibility to patients (Srivastava *et al.*, 2010).



Limitations

Variable Bioavailability

The bioavailability of phytochemicals can vary widely, affecting their efficacy and consistency in therapeutic outcomes (Manach *et al.*, 2004).

Lack of Standardization

Herbal remedies often lack standardized formulations, leading to variability in potency and quality between batches (Gafner & Bergeron, 2006).

Potential Side Effects

Despite their natural origin, plant-derived natural products can still cause adverse effects and drug interactions, particularly when consumed in high doses or in combination with other medications (Ernst, 2002).

Limited Clinical Evidence

While many plant-derived compounds show promise in preclinical studies, robust clinical evidence supporting their efficacy and safety in neurological disorders is often lacking (Sarris *et al.*, 2011).

Regulatory Challenges

Regulatory approval for herbal medicines can be complex, requiring rigorous evaluation of safety, efficacy, and quality standards (WHO, 2003).

Future Prospect

Some potential future prospects for the use of plant-derived natural products in the treatment of neurological disorders are listed below:

Advanced Formulations for Improved Bioavailability

Development of innovative formulations, such as nanocarriers and liposomal delivery systems, to enhance the bioavailability of plant-derived compounds and improve their efficacy (Sharma *et al.*, 2016).

Identification of Novel Compounds from Traditional Medicinal Plants

Continued exploration of traditional medicinal plants for the identification and isolation of novel bioactive compounds with therapeutic potential in neurological disorders (Heinrich *et al.*, 2020).

Personalized Medicine Approaches

Integration of genomic and metabolomic data to develop personalized medicine approaches, allowing targeted use of specific plant-derived compounds based on individual patient profiles (Wink, 2012).

Synergistic Combinations with Conventional Therapies

Exploration of synergistic interactions between plant-derived compounds and conventional pharmaceuticals to enhance therapeutic outcomes and reduce side effects (Amirkia & Heinrich, 2015).

Neuroprotective Effects in Aging and Age-Related Neurodegenerative Diseases

Investigation of the neuroprotective effects of plant-derived compounds in the context of aging and age-related neurodegenerative diseases, such as Alzheimer's and Parkinson's (Farzaei *et al.*, 2018).

Clinical Trials and Translational Research

Increased focus on conducting well-designed clinical trials to establish the safety and efficacy of plant-derived natural products in neurological disorders, facilitating their translation into mainstream medical practice (Heinrich, 2020).

Regulatory Frameworks and Quality Standards

Establishment of robust regulatory frameworks and quality standards for herbal medicines to ensure consistency, safety, and efficacy in the utilization of plant-derived natural products for neurological disorders (WHO, 2003).

- *Development of Novel Formulations*

Future research may focus on the development of novel formulations to enhance the bioavailability and stability of plant-derived natural products, thereby improving their efficacy and consistency in therapeutic outcomes (Manach *et al.*, 2004).

- *Identification of Novel Compounds*

Advances in technology, such as high-throughput screening and computational modeling, may facilitate the discovery of novel bioactive compounds from plant sources with enhanced therapeutic potential and specific targeting of neurological disease pathways (Newman & Cragg, 2016).

- *Combination Therapies*

There is growing interest in exploring the potential synergistic effects of combining plant-derived natural products with conventional pharmacological agents or other natural compounds, aiming to enhance therapeutic efficacy and overcome drug resistance mechanisms (Wagner & Ulrich-Merzenich, 2009).

- *Personalized Medicine Approaches*

Future research may focus on implementing personalized medicine approaches to optimize treatment strategies based on individual patient characteristics, including genetic factors, metabolic profiles, and disease severity, to maximize therapeutic benefits and minimize adverse effects (Sarris *et al.*, 2011).

- *Clinical Translation and Validation*

Continued efforts are needed to translate promising preclinical findings into clinical trials to validate the efficacy and safety of plant-derived natural products in neurological disorders. Well-designed clinical studies with rigorous methodologies are essential to establish evidence-based recommendations for their use in clinical practice (Devinsky *et al.*, 2017).

- *Regulatory Approval and Standardization*

Regulatory agencies need to establish clear guidelines for the evaluation, approval, and quality control of plant-derived natural products as therapeutic agents for neurological disorders. Standardization of herbal preparations and quality assurance measures are crucial to ensure product safety, efficacy, and consistency (WHO, 2003).

DISCUSSION

The use of plant-derived natural products in neurological disorders encompasses a wide range of topics, including their applications, advantages, limitations, future prospects, and implications for clinical practice and research.

Plant-derived natural products offer a diverse array of bioactive compounds with potential therapeutic benefits for various neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression. These compounds, such as curcumin, cannabidiol, and St. John's Wort extract, have demonstrated neuroprotective, anti-inflammatory, and antioxidant properties, making them attractive candidates for drug development (Lim *et al.*, 2001; Devinsky *et al.*, 2017; Hausenblas *et al.*, 2013).

One of the key advantages of plant-derived natural products is their natural origin, which is often associated with perceived safety and reduced risk of adverse effects compared to synthetic drugs. Additionally, these compounds exhibit diverse pharmacological activities and may act through multiple mechanisms, allowing for a holistic approach to treating neurological disorders (Fabricant & Farnsworth, 2001; Newman & Cragg, 2016). Even though their potential, the use of plant-derived natural products in neurological disorders is not without limitations. One of the primary challenges is the variability in bioavailability and potency of these compounds, which can impact their efficacy and consistency in therapeutic outcomes (Manach *et al.*, 2004). Additionally, the lack of standardized formulations and quality control measures poses challenges in ensuring product safety and reliability (Gafner & Bergeron, 2006).

Moreover, plant-derived natural products may still carry the risk of adverse effects and drug interactions, highlighting the importance of cautious use and close monitoring, especially when combined with other medications (Ernst, 2002). Regulatory hurdles and the need for rigorous clinical evidence further complicate their integration into mainstream healthcare practice (Sarris *et al.*, 2011).

Despite these challenges, there are several promising avenues for future research and development in this field. Advances in technology, such as high-throughput screening and computational modeling, hold the potential to expedite the discovery of novel bioactive compounds from plant sources (Newman & Cragg, 2016). Moreover, the development of novel formulations and personalized medicine approaches may optimize treatment strategies

and improve therapeutic outcomes (Wagner & Ulrich-Merzenich, 2009; Sarris *et al.*, 2011).

Collaborative efforts between researchers, healthcare professionals, and regulatory agencies are essential to address regulatory concerns, establish standardized protocols, and facilitate the translation of preclinical findings into clinical practice (WHO, 2003). By overcoming these challenges and harnessing the therapeutic potential of plant-derived natural products, we can potentially offer safer, more effective treatment options for neurological disorders, ultimately improving patient outcomes and quality of life.

CONCLUSION

In conclusion, the diverse applications, advantages, limitations, and future prospects of using plant-derived natural products in the management of neurological disorders. These natural compounds, ranging from curcumin to cannabidiol, exhibit a myriad of pharmacological activities, including neuroprotection, anti-inflammatory, and antioxidant effects, making them promising candidates for drug development.

While plant-derived natural products offer several advantages, such as their natural origin and diverse pharmacological activities, they also present challenges, including variability in bioavailability, lack of standardization, and potential side effects. Overcoming these challenges requires concerted efforts from researchers, healthcare professionals, and regulatory agencies to establish standardized protocols, ensure product safety, and facilitate clinical translation.

Looking ahead, future research may focus on the development of novel formulations, identification of novel compounds, and implementation of personalized medicine approaches to optimize treatment strategies and improve therapeutic outcomes. Collaborative efforts and rigorous clinical trials are essential to validate the efficacy and safety of plant-derived natural products in neurological disorders and to pave the way for their integration into mainstream healthcare practice.

By addressing these challenges and capitalizing on the therapeutic potential of plant-derived natural products, we can potentially offer safer, more effective treatment options for neurological disorders, ultimately enhancing patient care and quality of life.

ACKNOWLEDGEMENT

The authors extend deepest regards to management of Maharishi University of Information Technology for providing time and encouragement for this review work.

REFERENCES

- Aktas, O., Prozorovski, T., Smorodchenko, A., Savaskan, N. E., Lauster, R., Kloetzel, P. M., Hartung, H. P. (2004). Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. *Journal of Immunology*, 173(9), 5794-5800.



- Amirkia, V., & Heinrich, M. (2015). Natural products and drug discovery: A survey of stakeholders in industry and academia. *Frontiers in Pharmacology*, 6, 237.
- Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. *Cochrane Database of Systematic Reviews*, 2009(1), CD003120.
- Blanchet, J., Longpré, F., Bureau, G., Morissette, M., Di Paolo, T., & Bronchti, G. (2008). Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 32(5), 1243-1250.
- Butterweck, V., & Nahrstedt, A. (2010). What is the best strategy for preclinical testing of botanicals? A critical perspective. *Planta Medica*, 76(6), 572-581.
- Butterweck, V., Jurgenliemk, G., Nahrstedt, A., Winterhoff, H., & Korte, B. (2003). Hypericum perforatum: identification of the pharmacologically active constituents with a selective serotonin reuptake inhibitor activity. *Pharmacopsychiatry*, 36(S 01), 31-35.
- Cohen, J. A., Barkhof, F., Comi, G., Hartung, H. P., Khatri, B. O., Montalban, X., Panzara, M. A. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *New England Journal of Medicine*, 362(5), 402-415.
- Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Cilio, M. R. (2017). Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. *The Lancet Neurology*, 16(3), 171-178.
- Ernst, E. (2002). The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. *Annals of Internal Medicine*, 136(1), 42-53.
- Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. *Environmental Health Perspectives*, 109(Suppl 1), 69-75.
- Farnsworth, N. R., Akerele, O., Bingel, A. S., Soejarto, D. D., & Guo, Z. (1985). Medicinal plants in therapy. *Bulletin of the World Health Organization*, 63(6), 965-981.
- Farzaei, M. H., Bahramsoltani, R., Rahimi, R., & Abbasabadi, Z. (2018). Plant-derived natural products in the treatment of Alzheimer's and Parkinson's diseases. *Current Drug Metabolism*, 19(5), 429-438.
- Gafner, S., & Bergeron, C. (2006). [Botanical medicine standards—a call to action. *Planta Medica*, 72(10), 861-864.
- Gertsch, J. (2008). Anti-inflammatory cannabinoids in diet: towards a better understanding of CB2 receptor action? *Communicative & Integrative Biology*, 1(1), 26-28.
- Gupta, Y. K., Sharma, M., & Katiyar, C. K. (2002). A possible mechanism of action of quercetin as an anti-epileptic agent. *Methods and Findings in Experimental and Clinical Pharmacology*, 24(10), 675-678.
- Hausenblas, H. A., Saha, D., Dubyak, P. J., & Anton, S. D. (2013). Saffron (*Crocus sativus L.*) and major depressive disorder: A meta-analysis of randomized clinical trials. *Journal of Integrative Medicine*, 11(6), 377-383.
- Heinrich, M. (2020). Ethnopharmacology and drug development. In *Ethnopharmacology* (pp. 269-280). John Wiley & Sons.
- Heinrich, M., Appendino, G., Efferth, T., Fürst, R., Izzo, A. A., Kayser, O., iljoen, A. (2020). Best practice in research - Overcoming common challenges in phytopharmacological research. *Journal of Ethnopharmacology*, 246, 112230.
- Howes, M. J., & Houghton, P. J. (2003). Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. *Pharmacology Biochemistry and Behavior*, 75(3), 513-527.
- Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. *The Lancet*, 386(9996), 896-912.
- Katzenschlager, R., Evans, A., Manson, A., Patsalos, P. N., Ratnaraj, N., Watt, H., Lees, A. J. (2004). Mucuna pruriens in Parkinson's disease: A double blind clinical and pharmacological study. *Journal of Neurology, Neurosurgery & Psychiatry*, 75(12), 1672-1677.
- Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *Journal of Neuroscience*, 21(21), 8370-8377.
- Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: Food sources and bioavailability. *American Journal of Clinical Nutrition*, 79(5), 727-747.
- Naoi, M., & Maruyama, W. (2009). Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. *Expert Review of Neurotherapeutics*, 9(8), 1233-1250.
- Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs over the 30 years from 1981 to 2010. *Journal of Natural Products*, 75(3), 311-335.
- Raskin, I., *et al.* (2002). Medicine from nature: biodiversity, natural products, and the future of drug discovery. *Bio/Technology*, 20(1), 33-39.
- Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. *Therapeutics and Clinical Risk Management*, 4(1), 245-259.
- Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-1364.
- Sarris, J., *et al.* (2012). Herbal medicine for depression, anxiety, and insomnia: a review of psychopharmacology and clinical evidence. *European Neuropsychopharmacology*, 21(12), 841-860.
- Sarris, J., *et al.* (2013). Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. *CNS Drugs*, 27(4), 301-319.
- Sarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011). Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. *European Neuropsychopharmacology*, 21(12), 841-860.
- Sharma, P., Dube, B., & Sinha, N. (2016). Nanocarrier-based drug delivery systems for the treatment of neurodegenerative disorders. *Journal of Drug Targeting*, 24(8), 671-686.
- Srivastava, J. K., Shankar, E., & Gupta, S. (2010). Chamomile: A herbal medicine of the past with bright future. *Molecular Medicine Reports*, 3(6), 895-901.
- Wagner, H., & Ulrich-Merzenich, G. (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. *Phytomedicine*, 16(2-3), 97-110.
- Wang, W., *et al.* (2014). Neuroprotective effects of phytochemicals on dopaminergic neuron cultures. *Neurotoxicity Research*, 26(4), 363-379.
- Wink, M. (2012). Medicinal plants: A source of anti-parasitic secondary metabolites. *Molecules*, 17(11), 12771-12791.
- World Health Organization. (2003). WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva: World Health Organization.
- World Health Organization. (2020). Neurological Disorders: Public Health Challenges. Retrieved from https://www.who.int/mental-health/neurology/neurological_disorders_report_web.pdf

HOW TO CITE THIS ARTICLE: Prakash, S., Verma, S. Harnessing the Therapeutic Potential of Plant-Derived Natural Products in Neurological Disorders. *J. of Drug Disc. and Health Sci.* 2024;1(1):28-33.